Roche Strikes Up To $1.53 Billion Simcere Deal For SIM0660, Extending Its Asia Licensing Run

Roche has licensed Simcere Zaiming’s trispecific antibody SIM0660 in a deal that includes $75 million upfront and up to $1.53 billion in total payments, plus royalties, giving the Swiss drugmaker global rights to develop, manufacture and commercialize the asset. Simcere Zaiming, a subsidiary of China’s Simcere Pharmaceutical Group, said the program has potential in B-cell-mediated diseases, while a Roche spokesperson said the focus of the collaboration will be on malignancies.

The transaction adds to Roche’s recent burst of Asia partnering. One source described the Simcere agreement as Roche’s third licensing deal in the region in just over a week, following a Hanmi Pharma obesity pact and a DualityBio antibody-drug conjugate collaboration.

The Asset

SIM0660 is described as a trispecific antibody targeting CD79a, CD19 and CD3. Simcere said the molecule uses a CD3-engaging arm to bind T cells alongside domains directed at the B-cell antigens CD79a and CD19, with the design intended to trigger cytotoxicity while limiting cytokine release that can contribute to adverse safety events.

The companies framed that biology as potentially useful in patients who have already received CD20- or CD19-directed therapies. Simcere also said the dual targeting of CD79a and CD19 could support use across B-cell-mediated diseases, including autoimmune conditions such as lupus and arthritis.

The sources differ on development stage. BioSpace reported that SIM0660 is currently in early-stage clinical trials evaluating safety, tolerability, pharmacokinetics and efficacy in B-cell-mediated diseases, including newly diagnosed and relapsed/refractory B-cell lymphoma, citing a Roche spokesperson. Fierce Biotech described SIM0660 as preclinical.

The Strategic Picture

For Roche, the signal is less about one asset than about sourcing strategy. After the Hanmi and DualityBio agreements, the Simcere deal shows continued willingness to buy into externally generated programs from Asia at an early stage, using relatively modest upfront cash for optionality on larger milestone structures.

For Simcere, the agreement extends a broader out-licensing pattern. The pharmaceutical group said it has completed six out-licensing transactions worth a potential aggregate total of more than $6.1 billion if milestones are met, including a January deal with Boehringer Ingelheim tied to a preclinical inflammatory bowel disease antibody. That makes SIM0660 part of a larger monetization model in which Chinese developers convert early pipeline assets into international partnering revenue before registrational risk and launch spending begin.